

Permission to reproduce is granted if proper credit is given.

SUGGESTED CITATION:

Pharmaceutical Research and Manufacturers of America (PhRMA).  
*Pharmaceutical Industry Profile 2004* (Washington, DC: PhRMA, 2004).

Copyright © 2004 by the Pharmaceutical Research and Manufacturers of America.

Pharmaceutical Research and Manufacturers of America  
1100 Fifteenth Street, NW, Washington, DC 20003

[www.phrma.org](http://www.phrma.org)

2004

# List of Tables

## R&D, PhRMA Member Companies

1. Domestic R&D and R&D Abroad, PhRMA Member Companies: 1970–2003 . . . . .	39
2. R&D as a Percentage of Sales, PhRMA Member Companies: 1970–2003 . . . . .	40
3. Domestic R&D and R&D Abroad, PhRMA Member Companies: 2002–2003 . . . . .	41
4. R&D By Geographic Area, PhRMA Member Companies: 2002 . . . . .	42
5. Domestic R&D By Function, PhRMA Member Companies: 2002 . . . . .	43
6. Domestic R&D Scientific, Professional, and Technical Personnel By Function, PhRMA Member Companies: 2002 . . . . .	43

## Sales, PhRMA Member Companies

7. Domestic Sales and Sales Abroad, PhRMA Member Companies: 1970–2003 . . . . .	44
8. Domestic Sales and Sales Abroad By End Use and Customer, PhRMA Member Companies: 2002 . . . . .	45
9. Sales By Geographic Area, PhRMA Member Companies: 2002 . . . . .	46

**Table 1**  
**Domestic R&D and R&D Abroad\*\*, PhRMA Member Companies: 1970–2003**

(dollar figures in millions)

Year	Domestic R&D	Annual Percentage Change	R&D Abroad**	Annual Percentage Change	Total R&D	Annual Percentage Change
*2003	\$27,407.1	6.8%	\$5,808.3	8.4%	\$33,215.4	7.1%
2002	25,655.1	9.2	5,357.2	-13.9	31,012.2	4.2
2001	23,502.0	10.0	6,220.6	33.3	29,772.7	14.4
2000	21,363.7	15.7	4,667.1	10.6	26,030.8	14.7
1999	18,471.1	7.4	4,219.6	9.9	22,690.7	8.2
1998	17,127.9	11.0	3,839.0	9.9	20,996.9	10.8
1997	15,466.0	13.9	3,492.1	6.5	18,958.1	12.4
1996	13,627.1	14.8	3,278.5	-1.6	16,905.6	11.2
1995	11,874.0	7.0	3,333.5	***	15,207.4	***
1994	11,101.6	6.0	2,347.8	3.8	13,449.4	5.6
1993	10,477.1	12.5	2,262.9	5.0	12,740.0	11.1
1992	9,312.1	17.4	2,155.8	21.3	11,467.9	18.2
1991	7,928.6	16.5	1,776.8	9.9	9,705.4	15.3
1990	6,802.9	13.0	1,617.4	23.6	8,420.3	14.9
1989	6,021.4	15.0	1,308.6	0.4	7,330.0	12.1
1988	5,233.9	16.2	1,303.6	30.6	6,537.5	18.8
1987	4,504.1	16.2	998.1	15.4	5,502.2	16.1
1986	3,875.0	14.7	865.1	23.8	4,740.1	16.2
1985	3,378.7	13.3	698.9	17.2	4,077.6	13.9
1984	2,982.4	11.6	596.4	9.2	3,578.8	11.2
1983	2,671.3	17.7	546.3	8.2	3,217.6	16.0
1982	2,268.7	21.3	505.0	7.7	2,773.7	18.6
1981	1,870.4	20.7	469.1	9.7	2,339.5	18.4
1980	1,549.2	16.7	427.5	42.8	1,976.7	21.5
1979	1,327.4	13.8	299.4	25.9	1,626.8	15.9
1978	1,166.1	9.7	237.9	11.6	1,404.0	10.0
1977	1,063.0	8.1	213.1	18.2	1,276.1	9.7
1976	983.4	8.8	180.3	14.1	1,163.7	9.6
1975	903.5	13.9	158.0	7.0	1,061.5	12.8
1974	793.1	12.0	147.7	26.3	940.8	14.0
1973	708.1	8.1	116.9	64.0	825.0	13.6
1972	654.8	4.5	71.3	24.9	726.1	6.2
1971	626.7	10.7	57.1	9.2	683.8	10.6
1970	566.2	-----	52.3	-----	618.5	-----
<b>Average</b>		<b>12.8%</b>		<b>16.6%</b>		<b>13.4%</b>

\*Estimated

\*\*R&D Abroad includes expenditures outside the United States by U.S.-owned PhRMA member companies and R&D conducted abroad by the U.S. divisions of foreign-owned PhRMA member companies. R&D performed abroad by the foreign divisions of foreign-owned PhRMA member companies is excluded. Domestic R&D, however, includes R&D expenditures within the United States by all PhRMA member companies.

\*\*\*R&D Abroad affected by merger and acquisition activity.

Notes: All figures include company-financed R&D only. Total values may be affected by rounding.

Source: Pharmaceutical Research and Manufacturers of America, PhRMA Annual Membership Survey, 2004.

**Table 2**  
**R&D as a Percentage of Sales,**  
**PhRMA Member Companies: 1970–2003**

<b>Year</b>	<b>Domestic R&amp;D as a % of Domestic Sales</b>	<b>Total R&amp;D as a % of Total Sales</b>
*2003	17.7%	15.6%
2002	18.4	16.1
2001	18.3	16.7
2000	18.4	16.2
1999	18.2	15.5
1998	21.1	16.8
1997	21.6	17.1
1996	21.0	16.6
1995	20.7	16.7
1994	21.9	17.3
1993	21.6	17.0
1992	19.4	15.5
1991	17.9	14.6
1990	17.7	14.4
1989	18.4	14.8
1988	18.3	14.1
1987	17.4	13.4
1986	16.4	12.9
1985	16.3	12.9
1984	15.6	12.1
1983	15.8	11.8
1982	15.4	10.9
1981	14.7	10.0
1980	13.1	8.9
1979	12.4	8.6
1978	12.1	8.5
1977	12.3	9.0
1976	12.2	8.9
1975	12.5	9.0
1974	12.1	9.1
1973	12.3	9.3
1972	12.4	9.2
1971	12.0	9.0
1970	12.3	9.3

\*Estimated

*Source: Pharmaceutical Research and Manufacturers of America, PhRMA Annual Membership Survey, 2004.*

**Table 3**  
**Domestic R&D and R&D Abroad\*\*, PhRMA Member Companies:**  
**2002–2003**

(dollar figures in millions)

	2002	*2003
<b>R&amp;D Expenditures for Human-Use Pharmaceuticals</b>		
Domestic	\$25,363.2	\$27,088.6
Share	81.8%	81.6%
Abroad**	\$ 5,264.4	\$ 5,712.4
Share	17.0%	17.2%
<b>Total Human-Use R&amp;D</b>	<b>\$30,627.6</b>	<b>\$32,801.0</b>
Share	98.8%	98.8%
<b>R&amp;D Expenditures for Veterinary-Use Pharmaceuticals</b>		
Domestic	\$ 291.8	\$ 318.5
Share	0.9%	1.0%
Abroad**	\$ 92.8	\$ 95.9
Share	0.3%	0.3%
<b>Total Vet-Use R&amp;D</b>	<b>\$ 384.6</b>	<b>\$ 414.4</b>
Share	1.2%	1.2%
<b>TOTAL R&amp;D</b>	<b>\$31,012.2</b>	<b>\$33,215.4</b>
	100.0%	100.0%

\*Estimated

\*\*R&D Abroad includes expenditures outside the United States by U.S.-owned PhRMA member companies and R&D conducted abroad by the U.S. divisions of foreign-owned PhRMA member companies. R&D performed abroad by the foreign divisions of foreign-owned PhRMA member companies is excluded. Domestic R&D, however, includes R&D expenditures within the United States by all PhRMA member companies.

*Notes: All figures include company-financed R&D only. Total values may be affected by rounding.*

*Source: Pharmaceutical Research and Manufacturers of America, PhRMA Annual Membership Survey, 2004.*

**Table 4**  
**R&D By Geographic Area\*, PhRMA Member Companies: 2002**

(dollar figures in millions)

<b>Geographic Area*</b>	<b>Dollars</b>	<b>Share</b>
<b>Africa</b>		
Africa	\$ 14.4	0.0%
<b>Americas</b>		
United States	\$25,655.1	82.7%
Canada	304.5	1.0
Latin America (South and Central America, Mexico, and all Caribbean nations)	113.4	0.4%
<b>Asia-Pacific</b>		
Asia-Pacific (except Japan)	\$ 79.2	0.3%
India and Pakistan	3.1	0.0
Japan	706.4	2.3
<b>Australia</b>		
Australia and New Zealand	\$ 80.0	0.3%
<b>Europe</b>		
France	\$ 378.8	1.2%
Germany	401.2	1.3
Italy	232.2	0.7
Spain	125.3	0.4
United Kingdom	1,324.9	4.3
Other Western European	1,453.6	4.7
Central and Eastern Europe (Cyprus, Czech Republic, Estonia, Hungary, Poland, Slovenia, Bulgaria, Lithuania, Latvia, Romania, Slovakia, and Malta)	91.4	0.3
Other Eastern European (including Russia and the Newly Independent States)	13.4	0.0
<b>Middle East</b>		
Middle East (Saudi Arabia, Yemen, United Arab Emirates, Iraq, Iran, Kuwait, Israel, Jordan, Syria, Afghanistan, Turkey, and Qatar)	\$ 24.5	0.1%
<b>Uncategorized</b>		
	\$ 10.8	0.0%
<b>TOTAL R&amp;D</b>	<b>\$31,012.2</b>	<b>100.0%</b>

\*R&D Abroad includes expenditures outside the United States by U.S.-owned PhRMA member companies and R&D conducted abroad by the U.S. divisions of foreign-owned PhRMA member companies. R&D performed abroad by the foreign divisions of foreign-owned PhRMA member companies is excluded. Domestic R&D, however, includes R&D expenditures within the United States by all PhRMA member companies.

Notes: All figures include company-financed R&D only. Total values may be affected by rounding.

Source: Pharmaceutical Research and Manufacturers of America, PhRMA Annual Membership Survey, 2004.

**Table 5**  
**Domestic R&D By Function, PhRMA Member Companies: 2002**

(dollar figures in millions)

<b>Function</b>	<b>Dollars</b>	<b>Share</b>
Prehuman/Preclinical	\$10,481.6	33.8%
Phase I	1,490.2	4.8
Phase II	2,968.1	9.6
Phase III	6,286.4	20.2
Approval	2,455.0	7.9
Phase IV	3,855.2	12.4
Uncategorized	3,493.7	11.3
<b>TOTAL R&amp;D</b>	<b>\$31,012.2</b>	<b>100.0%</b>

*Notes: All figures include company-financed R&D only. Total values may be affected by rounding.*

*Source: Pharmaceutical Research and Manufacturers of America, PhRMA Annual Membership Survey, 2004.*

**Table 6**  
**Domestic R&D Scientific, Professional, and Technical Personnel By Function, PhRMA Member Companies: 2002**

<b>Function</b>	<b>Personnel</b>	<b>Share</b>
Prehuman/Preclinical	30,555	40.4%
Phase I	4,465	5.9
Phase II	6,431	8.5
Phase III	16,670	22.0
Approval	5,235	6.9
Phase IV	7,867	10.4
<b>Total R&amp;D Staff</b>	<b>71,223</b>	<b>94.1%</b>
Supported R&D Nonstaff	4,472	5.9
<b>TOTAL R&amp;D PERSONNEL</b>	<b>75,695</b>	<b>100.0%</b>

*Source: Pharmaceutical Research and Manufacturers of America, PhRMA Annual Membership Survey, 2004.*

**Table 7**  
**Domestic Sales and Sales Abroad\*\*, PhRMA Member Companies: 1970–2003**

(dollar figures in millions)

Year	Domestic Sales	Annual Percentage Change	Sales Abroad**	Annual Percentage Change	Total Sales	Annual Percentage Change
*2003	\$154,641.6	11.1%	\$58,061.6	8.1%	\$212,703.2	10.3%
2002	139,136.4	6.4	53,697.4	12.1	192,833.8	8.0
2001	130,715.9	12.8	47,886.9	5.9	178,602.8	10.9
2000	115,881.8	14.2	45,199.5	1.6	161,081.3	10.4
1999	101,461.8	24.8	44,496.6	2.7	145,958.4	17.1
1998	81,289.2	13.3	43,320.1	10.8	124,609.4	12.4
1997	71,761.9	10.8	39,086.2	6.1	110,848.1	9.1
1996	64,741.4	13.3	36,838.7	8.7	101,580.1	11.6
1995	57,145.5	12.6	33,893.5	***	91,039.0	***
1994	50,740.4	4.4	26,870.7	1.5	77,611.1	3.4
1993	48,590.9	1.0	26,467.3	2.8	75,058.2	1.7
1992	48,095.5	8.6	25,744.2	15.8	73,839.7	11.0
1991	44,304.5	15.1	22,231.1	12.1	66,535.6	14.1
1990	38,486.7	17.7	19,838.3	18.0	58,325.0	17.8
1989	32,706.6	14.4	16,817.9	-4.7	49,524.5	7.1
1988	28,582.6	10.4	17,649.3	17.1	46,231.9	12.9
1987	25,879.1	9.4	15,068.4	15.6	40,947.5	11.6
1986	23,658.8	14.1	13,030.5	19.9	36,689.3	16.1
1985	20,742.5	9.0	10,872.3	4.0	31,614.8	7.3
1984	19,026.1	13.2	10,450.9	0.4	29,477.0	8.3
1983	16,805.0	14.0	10,411.2	-2.4	27,216.2	7.1
1982	14,743.9	16.4	10,667.4	0.1	25,411.3	9.0
1981	12,665.0	7.4	10,658.3	1.4	23,323.3	4.6
1980	11,788.6	10.7	10,515.4	26.9	22,304.0	17.8
1979	10,651.3	11.2	8,287.8	21.0	18,939.1	15.3
1978	9,580.5	12.0	6,850.4	22.2	16,430.9	16.1
1977	8,550.4	7.5	5,605.0	10.2	14,155.4	8.6
1976	7,951.0	11.4	5,084.3	9.7	13,035.3	10.8
1975	7,135.7	10.3	4,633.3	19.1	11,769.0	13.6
1974	6,740.4	13.8	3,891.0	23.4	10,361.4	17.2
1973	5,686.5	9.1	3,152.5	15.9	8,839.0	11.5
1972	5,210.1	1.3	2,720.2	10.6	7,930.3	4.3
1971	5,144.9	13.0	2,459.7	18.0	7,604.6	14.6
1970	4,552.5	-----	2,084.0	-----	6,636.5	-----
<b>Average</b>		<b>11.4%</b>		<b>10.5%</b>		<b>11.0%</b>

\*Estimated

\*\*Sales Abroad includes sales generated outside the United States by U.S.-owned PhRMA member companies and sales generated abroad by the U.S. divisions of foreign-owned PhRMA member companies. Sales generated abroad by the foreign divisions of foreign-owned PhRMA member companies are excluded. Domestic sales, however, includes sales generated within the United States by all PhRMA member companies.

\*\*\*Sales Abroad affected by merger and acquisition activity.

Note: Total values may be affected by rounding.

Source: Pharmaceutical Research and Manufacturers of America, PhRMA Annual Membership Survey, 2004.

**Table 8**  
**Domestic Sales and Sales Abroad\* By End Use and Customer, PhRMA**  
**Member Companies: 2002**

(dollar figures in millions)

	Human Use	Vet Use	Total
To Private Sector	\$131,203.3	\$ 1,300.7	\$132,504.0
To Public Sector	6,473.0	159.4	6,632.4
<b>Total Domestic Sales</b>	<b>\$137,676.3</b>	<b>\$ 1,460.1</b>	<b>\$139,136.4</b>
Exports	\$ 864.7	\$ 61.0	\$ 925.7
Foreign Sales	51,293.2	1,478.5	52,771.7
<b>Total Sales Abroad*</b>	<b>\$ 52,157.9</b>	<b>\$ 1,539.5</b>	<b>\$ 53,697.4</b>
<b>TOTAL SALES</b>	<b>\$189,834.2</b>	<b>\$ 2,999.6</b>	<b>\$192,833.8</b>

\*Sales Abroad includes sales generated outside the United States by U.S.-owned PhRMA member companies and sales generated abroad by the U.S. divisions of foreign-owned PhRMA member companies. Sales generated abroad by the foreign divisions of foreign-owned PhRMA member companies are excluded. Domestic sales, however, includes sales generated within the United States by all PhRMA member companies.

*Note: Total values may be affected by rounding.*

*Source: Pharmaceutical Research and Manufacturers of America, PhRMA Annual Membership Survey, 2004.*

**Table 9**  
**Sales By Geographic Area\*, PhRMA Member Companies: 2002**

(dollar figures in millions)

<b>Geographic Area*</b>	<b>Dollars</b>	<b>Share</b>
<b>Africa</b>		
Africa	\$ 549.8	0.3%
<b>Americas</b>		
United States	\$139,136.4	72.2%
Canada	3,415.2	1.8
Latin America (South and Central America, Mexico, and all Caribbean nations)	4,583.7	2.4
<b>Asia-Pacific</b>		
Asia-Pacific (except Japan)	\$ 2,560.0	1.3%
India and Pakistan	483.8	0.3
Japan	6,366.9	3.3
<b>Australia</b>		
Australia and New Zealand	\$ 1,555.8	0.8%
<b>Europe</b>		
France	\$ 5,097.2	2.6%
Germany	4,139.1	2.1
Italy	3,893.4	2.0
Spain	2,522.5	1.3
United Kingdom	3,822.9	2.0
Other Western European	7,090.0	3.7
Central and Eastern Europe (Cyprus, Czech Republic, Estonia, Hungary, Poland, Slovenia, Bulgaria, Lithuania, Latvia, Romania, Slovakia, and Malta)	1,390.8	0.7
Other Eastern European (including Russia and the Newly Independent States)	321.3	0.2
<b>Middle East</b>		
Middle East (Saudi Arabia, Yemen, United Arab Emirates, Iraq, Iran, Kuwait, Israel, Jordan, Syria, Afghanistan, Turkey, and Qatar)	\$ 1,362.3	0.7%
<b>Uncategorized</b>	\$ 4,542.7	2.4%
<b>TOTAL SALES</b>	<b>\$192,833.8</b>	<b>100.0%</b>

\*Sales Abroad includes sales generated outside the United States by U.S.-owned PhRMA member companies and sales generated abroad by the U.S. divisions of foreign-owned PhRMA member companies. Sales generated abroad by the foreign divisions of foreign-owned PhRMA member companies are excluded. Domestic sales, however, includes sales generated within the United States by all PhRMA member companies.

*Note: Total values may be affected by rounding.*

*Source: Pharmaceutical Research and Manufacturers of America, PhRMA Annual Membership Survey, 2004.*

# PhRMA Annual Membership Survey Definitions of Terms

## Research and Development (R&D) Definitions

**R&D Expenditures:** Expenditures within PhRMA member companies' U.S. and/or foreign research laboratories plus R&D funds contracted or granted to commercial laboratories, private practitioners, consultants, educational and nonprofit research institutions, manufacturing and other companies, or other research-performing organization.

**Prehuman/Preclinical Testing:** From synthesis to first testing in humans.

**Phase I/II/III Clinical Testing:** From first testing in designated phase to first testing in subsequent phase.

**Approval Phase:** From new drug application (NDA) submission to NDA approval.

**Phase IV Clinical Testing:** Any postmarketing testing performed.

**Uncategorized:** Represents data for which detailed classifications were unavailable.

**Scientific, Professional, and Technical Staff:** Full-time employees, as well as full-time equivalents for part-time employees, whose work requires the application of R&D knowledge, skills, and scientific techniques in the life, physical, engineering, mathematical, or statistical sciences as well as persons engaged in technical work at a level that requires knowledge in one of the above-mentioned fields. Does not include persons who have formal training in the sciences but who are not actively engaged in R&D.

**Supported Scientific, Professional, and Technical Nonstaff:** Persons whose work requires the application of R&D knowledge, skills, and scientific techniques in the life, physical, engineering, mathematical, or statistical sciences as well as persons engaged in technical work at a level that requires knowledge in one

of the above-mentioned fields who are supported through contracts or grants to commercial laboratories, private practitioners, consultants, educational and nonprofit research institutions, manufacturing and other companies, or other research-performing organizations located in the United States. Does not include persons who have formal training in the sciences but who are not actively engaged in R&D.

## Sales Definitions

**Sales:** Product sales calculated as billed, free on board (FOB) plant or warehouse less cash discounts, Medicaid rebates, returns, and allowances. These include all marketing expenses except transportation costs. Also included is the sales value of products bought and resold without further processing or repackaging as well as the dollar value of products made from the firm's own materials for other manufacturers' resale. Excluded are all royalty payments, interest, and other income.

**Exports to Other Customers:** Sales to third parties only, FOB U.S. port. Excludes all intrafirm transactions such as sales or shipments to subsidiaries or affiliates.

**Foreign Sales:** Sales consummated in foreign countries.